SMC accepts breakthrough treatment Entresto™ for use in patients with symptomatic chronic heart failure

Sacubitril/valsartan represents a breakthrough therapeutic option for adult patients with symptomatic chronic heart failure with reduced ejection fraction

Source: Pharmacy Europe - March 9, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Healthcare professionals Practical therapeutics Cardiovascular medicine Patient care chronic heart failure Latest News sacubitril/valsartan scottish medicines consortium Source Type: news